Month: September 2025

Clinical trial financial accruals require close coordination between clinical operations and finance departments. Unfortunately, many organizations suffer from misaligned processes, unclear roles, and inconsistent reporting.  

Why the Disconnect Around Clinical Trial Financial Accruals Exists 

Clinical and finance teams often work with different goals in mind. Clinical staff prioritize patient recruitment, site performance, and trial timelines. Finance teams, on the other hand, are focused on budget accuracy, cash flow, and monthly close deadlines. 

This misalignment creates situations where: 

• Clinical teams don’t report activities on time, leading to under-accrual. 
• Finance teams request cost estimates without understanding how studies are operationalized. 
• No one takes ownership of reconciling trial progress with financial reports. 

When both clinical and finance teams understand the goals of clinical trial financial accruals, collaboration becomes more effective. 

Consequences of Poor Collaboration 

Inaccurate Financial Reporting: Without timely and accurate input from clinical teams, finance departments may guess or delay their accruals, affecting external audits or investor confidence. 

Budget Overruns: Lack of transparency can cause clinical programs to exceed budgets before leadership realizes there’s a problem. 

Operational Bottlenecks: Time wasted on chasing down data or correcting accrual errors takes valuable attention away from study execution. 

Strategies to Strengthen Cross-Functional Collaboration 

Establish Shared Language and Goals: Develop a basic financial literacy program for clinical teams and help finance staff understand how trials progress. Align on key metrics that matter to both sides, such as cost-per-visit or site activation timelines. 

Hold Regular Joint Planning Sessions: Don’t wait until a problem arises. Schedule recurring meetings where clinical and finance leads review trial milestones, spending to date, and accrual estimates. 

Use Integrated Systems and Tools: Centralized clinical trial management systems (CTMS) that feed into finance systems can reduce manual reporting errors and create a single source of truth. 

Define Roles and Responsibilities: Clearly outline who is responsible for reporting site activity, updating vendor timelines, and submitting forecasts. Remove the guesswork from collaboration. 

Document Accrual Assumptions: Create audit trails and documentation for how accruals were estimated. This provides transparency and allows for better review in future months or trials. 

The Result? 

Proactive collaboration around clinical trial financial accruals leads to more accurate budgets, greater cross-functional trust, and improved trial efficiency. Looking to bridge the gap between clinical and finance teams? Danforth Health provides fractional finance support tailored to biotech and life science companies. We help teams align around accruals, budgeting, and forecasting for greater operational efficiency. Contact us today. 

Maintaining respectful, open dialogue at work has become more important and challenging than ever. The rise of social and political discourse spilling into work environments has left many leaders scrambling to manage civil discourse in the workplace, leaving them to wonder: How do we protect culture without stifling individuality? 

Managing civil discourse in the workplace starts with a proactive plan rooted in your company’s values. 

“When people don’t know the boundaries, it’s hard to enforce them. You have to be clear, not just in your policies, but in how you live them out day to day.” 

This statement, shared during our recent conversation with an expert Danforth Health HR consultant, captures the essence of managing workplace conflict. Your company culture is defined by how you approach disagreement, not just how you celebrate success. 

#1: Revisit Your Mission and Values 

When a workplace conflict arises, leadership must ask: Is this about behavior, or is it a deeper value misalignment? Reaffirming your mission and values can help guide that assessment. Make sure your team knows: 

1. What the company stands for 
2. What behaviors are encouraged 
3. What the non-negotiables are 

#2: Understand the Legal Landscape

There’s a common misconception that “free speech” protections automatically extend into the private workplace. In reality, free speech does not apply the same way within private organizations. Employers have the right to and the legal obligation to set boundaries, especially when speech veers into harassment, disruption, or discrimination. 

To manage civil discourse in the workplace, know what is and isn’t protected and train your managers accordingly. If your managers feel unsure about what they can address, they’ll often say nothing, and that silence can do real damage.

#3: Don’t Wait for the Fire- Build the Extinguisher Now 

Only 8% of organizations have a formal policy around civil discourse in the workplace. That’s a missed opportunity. A well-crafted civil discourse policy can: 

• Clarify behavioral expectations 
• Provide a roadmap for conflict resolution  
• Reinforce cultural norms 

Your action plan should include:

• A clearly communicated code of conduct  
• Manager training on conflict resolution and inclusive dialogue 
• A protocol for escalating and resolving issues 
• Being fully compliant with various sections of the National Labor Relations Act  

Is your organization prepared? Don’t wait for conflict or a legal issue to force your hand when it comes to managing civil discourse in the workplace. The time to define expectations and protect your culture is now. Danforth Health can help you build a proactive policy and response plan tailored to your organization. Contact us today. 

Too often, companies delay commercial strategy until late-stage development, assuming it’s a downstream task. However, the vast majority, 80–90% of drugs in development, must prioritize biotech commercial planning much earlier than they think. Delaying commercial readiness can create compounding risks that threaten your funding, your timeline, and your launch success. 

Here’s what’s at stake when biotech commercial planning gets pushed too far down the road. 

1. Reduced Investor or Acquirer Interest 

Investors and acquirers today expect a robust early commercial strategy to accompany your clinical plan. Without a compelling commercial narrative, you risk being overlooked in favor of competitors who can clearly demonstrate product-market fit and growth potential. 

Biotech companies that delay commercial planning often struggle to: 

• Secure critical funding. 
• Attract interest from potential acquirers or partners. 
• Build credibility with key stakeholders. 

Biotech commercial planning isn’t a nice-to-have; it’s a prerequisite for investor confidence. 

 2. Misalignment with Market, Patients, and Payers 

If you wait too long to engage commercial functions, your development path may overlook critical market factors: 

• Is your product differentiated enough? 
• Will payers reimburse it? 
• Are you solving a true unmet need? 

Without early insights from market research and payer engagement, you risk launching a product that doesn’t resonate, or worse, one that doesn’t get covered. 

 3. Launch Delays 

A delayed start to commercial planning in biotech often creates major gaps: 

• Incomplete market understanding. 
• Lack of secondary data to support claims. 
• Underdeveloped KOL or HCP engagement plans. 

These gaps can delay your biotech product launch by months or even years, ultimately reducing the product’s lifetime value and competitive edge. 

 4. Costly Last-Minute Changes 

When commercial needs come into focus late, the resulting pivots are often expensive: 

• Retrofitting clinical trials. 
• Rushing to collect new data. 
• Overhauling messaging or branding at the eleventh hour. 

All of these emergency efforts drive up costs and reduce launch efficiency. By contrast, early biotech commercial planning allows you to integrate commercial considerations from the outset: saving time, money, and resources. 

 5. Underperformance at Launch 

Studies show that only 20–30% of first-time launchers meet or exceed commercial expectations. Why? It’s rarely the science. More often, it’s the absence of a well-structured, realistic commercial plan. 

Companies that invest in commercial readiness early are far better equipped to: 

• Navigate payer negotiations. 
• Educate physicians and patients. 
• Build internal capabilities that support long-term growth. 

The Takeaway: Plan Early, Win Bigger 

If you’re not developing a first-in-class or ultra-orphan drug, the market won’t give you much breathing room. For most companies, biotech commercial planning should begin in Phase 2 or earlier, not post-approval. 

By prioritizing early market insight, stakeholder alignment, and strategic planning, your team can reduce risk and maximize the return on years of clinical effort. 

Need guidance on when and how to start your biotech commercial planning? 

Our team specializes in helping biopharma teams build commercial strategies that scale with development. Connect with us today. 

Insights From an Expert: Written by Chris Mycek, Head of Commercialization, BW Health Group, A Danforth Health Company

Applying Nature’s Growth Patterns to Life Sciences Commercialization

As we help clients navigate the complex world of life sciences commercialization strategy from clinical promise to commercial success, I’m struck by how often sustainable growth follows patterns found in nature. The Fibonacci sequence—where each number is the sum of the two preceding ones (1, 1, 2, 3, 5, 8, 13, 21…)—offers a compelling framework for thinking about organizational development in life sciences commercialization. What we’re looking to achieve is healthy, sustainable growth…so why not look to Mother Nature for an answer?

The Seed Stage: 1, 1

Every successful life sciences commercialization strategy begins with two fundamental elements that must be equally strong: a differentiated clinical asset and a clear understanding of unmet patient need. Like the first two numbers in the Fibonacci sequence, these elements stand alone yet together form the foundation for everything that follows.

Too often, I see pre-commercial organizations fixate exclusively on clinical data while underinvesting in market research. Both must receive equal attention. Even groundbreaking science fails commercially when disconnected from provider and patient realities.

Early Growth: 2, 3, 5

As organizations advance toward commercialization, each new capability should build upon established strengths. The “2” represents the initial commercial leadership—typically the Chief Commercial Officer and Medical Affairs lead who synthesize clinical and market insights into a coherent strategy.

The “3” emerges as this core team expands to include market access expertise—critical for today’s value-based reimbursement environment. These three functions together shape the “5”—the essential commercial workstreams: brand strategy, pricing architecture, distribution model, field deployment planning, and launch sequencing.

This natural progression prevents the common pitfall I witness repeatedly: prematurely scaling commercial infrastructure before foundational elements are solidified. In a successful life sciences commercialization strategy, each new function should emerge from and be supported by previous capabilities.

Accelerating Momentum: 8, 13, 21

As launch approaches, organizations face tremendous pressure to rapidly expand. The Fibonacci pattern reminds us that growth should accelerate naturally but proportionally. The “8” in this life sciences commercialization strategy represents the expanded commercial roles—adding sales leadership, marketing specialists, and account management strategists who build upon the core team’s vision.

The “13” often reflects field deployment. Here, I counsel clients to resist arbitrary size targets. Instead, align field force scale precisely with the strategic focus established earlier. Organizations that skip steps in this progression invariably struggle with misalignment and excessive burn rates.

The “21” represents the full commercial organization post-launch, including support functions, analytics teams, and expanded medical capabilities. When built according to this natural progression, these teams work with remarkable synchronicity.

Sustainable Balance

Nature employs the Fibonacci sequence because it creates balanced, sustainable systems. Similarly, the most successful life sciences commercialization strategy follows this organic pattern rather than artificially accelerated timelines that create organizational stress fractures.

For pre-commercial organizations, particularly those launching their first asset, the temptation to simultaneously build all commercial capabilities is almost irresistible. The Fibonacci framework offers a disciplined alternative: methodical capability building where each new function reinforces rather than dilutes organizational focus.

Practical Application

When advising clients on life sciences commercialization strategy, we now explicitly map organizational development against this Fibonacci framework. This approach has helped several recent clients:

• A Phase II oncology company reallocated resources from premature sales infrastructure to deeper market research, ultimately sharpening their differentiation strategy
• A rare disease organization restructured their hiring sequence to strengthen core market access capabilities before expanding marketing functions
• A CNS-focused company redesigned their launch timeline to ensure adequate integration between medical affairs and commercial teams before field expansion

The most elegant solutions in nature and business share a common characteristic: simplicity that creates sustainable complexity. By following the natural growth pattern of the Fibonacci sequence, life sciences organizations can build commercial capabilities that reinforce rather than compete with each other.

In an industry where overbuilding and subsequent restructuring have become distressingly common, this approach offers a path to more sustainable growth, with the potential to bring life-changing therapies to patients more efficiently and effectively.

Successful commercialization in life sciences doesn’t happen by chance; it requires the right team, the right timing, and the right strategy. That’s where we come in. Build your commercialization strategy the smart, scalable way. Contact our team today.

Immigration policy in biotech companies continues to evolve, and the biotech sector, with its reliance on international talent, faces unique challenges. Biotech workforce immigration issues are critical, but your organization can tackle immigration-related uncertainties with a proactive compliance plan that protects both your people and your business.

“When employees don’t know where they stand, it impacts morale, productivity, and retention. HR needs to be the steady voice in the room.” 

Here’s how to prepare:

#1: Immigration Compliance Checklist: How to Audit I-9 Forms, Utilize E-Verify, and Maintain Public Access Files in Biotech

Use this checklist to conduct an internal audit: 

• I-9 Forms: Conduct a formal I-9 audit. Ensure all are up to date and stored correctly. When it comes to filing, be sure all immigration-related paperwork is kept in a separate file. This may limit what must be provided during an investigation, raid, or legal proceeding. 
• e-Verify: Some companies are required to use E-Verify based on the state(s) in which they operate and any federal or state grants. Other companies may voluntarily choose to use E-Verify. For those who do use the system, ensure consistent and compliant use. If you’re not using E-Verify, you can be taking an unnecessary risk. 
• Public Access Files: If your organization employs H-1B visa holders, maintaining complete and compliant Public Access Files (PAFs) is a legal requirement, and one that can easily be overlooked until it’s too late. PAFs must be created within one working day of filing the Labor Condition Application (LCA) and must be readily accessible to any member of the public upon request. 
• Prepare well in advance for travel; any sponsored employee must fully understand their obligations and rights upon re-entry. 
• Manager Training: Do your employees know what to do if immigration agents come onsite? Do they know their rights? 

#2: When It Comes to Immigration Policy in Biotech: Know Your Rights and Responsibilities

Biotech companies must understand their legal responsibilities for immigration enforcement. Federal agents need a warrant to enter non-public workspaces, but many biotech employers don’t know their rights or freeze during the process. Having a biotech immigration plan can ensure you’re always prepared.

 Your plan should include: 

• A designated point person for government interactions 
• Immediate legal counsel contact 
• A communications protocol for affected employees 

#3: Keep Employees in the Loop (Especially When Immigration Policies Change)

Immigration concerns are deeply personal. Avoid radio silence. Instead: 

• Offer updates when policies change 
• Reaffirm your support for affected employees 
• Maintain confidentiality and compassion 

Biotech HR Strategies: How to Protect Your International Talent Now

In biotech, your people are your most powerful asset- and that includes your international talent. Navigating immigration uncertainty requires more than just compliance; it calls for clarity, compassion, and a clear plan. Danforth Health specializes in biotech immigration compliance and can help you create tailored response strategies to protect your team and business. Contact us to develop your readiness plan today.

The BIOSECURE Act, currently making its way through Congress, has the potential to create significant disruption across the U.S. biotechnology industry.

If enacted, BIOSECURE Act compliance will become mandatory for federally funded biotech companies, requiring them to sever ties with several key Chinese biotechnology firms. This shift could impact everything from R&D to supply chains, creating legal, operational, and financial risks for unprepared organizations. 

To ensure business continuity and reduce exposure, biotech leaders must begin preparing now. Here are five essential steps to build a BIOSECURE Act compliance strategy: 

BIOSECURE ACT Compliance Step #1: Assess Business Risks and Compliance Exposure  

Start by evaluating your organization’s current ties to restricted Chinese entities. 

1. Review dependencies across R&D, manufacturing, supply chains, and data storage. 
2. Identify any use of Chinese-owned technology or services. 
3. Engage legal counsel to analyze contract language and assess regulatory and legal liabilities. 

Being proactive helps reduce compliance gaps and mitigate enforcement risks. 

BIOSECURE ACT Compliance Step #2: Secure Intellectual Property and Mitigate Contract Risks

Strengthening your organization’s IP protections is a key part of BIOSECURE Act compliance. 

1. Take inventory of trade secrets, patents, and licensing agreements. 
2. Determine where IP relies on Chinese technology or vendors and assess alternatives. 
3. Revisit vendor contracts to evaluate termination clauses, financial penalties, and compliance triggers. 

This step ensures long-term IP security and shields your organization from unexpected legal or operational interruptions. 

BIOSECURE ACT Compliance Step #3: Diversify Vendors and Storage Strategies  

Reducing overreliance on Chinese partners is essential for BIOSECURE Act readiness. 

1. Identify and qualify alternate CDMOs and CROs in the U.S., India, Latin America, or the EU. 
2. Conduct due diligence on vendor capacity, certifications, and regulatory compliance. 
3. Set up redundant warehousing and distribution strategies to avoid bottlenecks. 

Vendor diversification will help ensure uninterrupted operations as the act’s provisions come into force. 

BIOSECURE ACT Compliance Step #4: Plan for Financial Impact and Transition Costs  

Complying with the BIOSECURE Act may require strategic financial planning. 

1. Estimate the full cost of vendor transitions, infrastructure updates, and regulatory adjustments. 
2. Compare the costs and benefits of onshoring vs. outsourcing to approved international vendors. 
3. Explore government incentives like tax credits, loan guarantees, and grants to offset costs. 
4. Prepare for potential countermeasures from China, including restrictions on biotech materials. 

BIOSECURE ACT Compliance Step #5: Protect Employees and Strengthen Cybersecurity  

BIOSECURE Act compliance also includes preparing for geopolitical risks. 

1. Create contingency plans for employees traveling to China, especially those at heightened risk under national security laws. 
2. Monitor updates from the U.S. State Department regarding travel and international trade risk. 
3. Bolster cybersecurity defenses to safeguard sensitive IP and company data from potential cyber threats or espionage. 

Stay Ahead of BIOSECURE Act Developments 

Even before the BIOSECURE Act becomes law, taking action now gives your organization a competitive advantage. Track updates to the Biotechnology Companies of Concern List and FAR regulations, and monitor whether additional countries are added to future legislation. 

Danforth Health’s compliance and risk management experts can guide you through this evolving landscape with practical, customized support. Contact us today. 

Preparing for a capital raise? A dynamic pro forma cap table is a must.

Private life science companies are nearly always looking towards their next financing event. Whether seed stage or Series C, stakeholders must understand in advance how their post-raise ownership might change based on wide-ranging assumptions, including the amount of their investment and the company’s current valuation. A pro forma cap table is used to model various outcomes to inform decision-making and set proper expectations before the deal is done. But one size does not fit all.

Pro forma cap table templates and services are abundant online, but they produce static statements that fall short of revealing the most accurate picture in real time. They don’t account for the full range or complexity of possible inputs, such as dilution protection for current shareholders or pre-existing convertible notes. In contrast, Danforth offers a dynamic, customized pro forma cap table that can reveal all possible outcomes, in real time, with the assuredness required by company founders and leaders, directors, shareholders and prospective investors.

How We Help

• An expertly-built tool – Designed and customized by experts in financial planning and analysis with many decades of experience in modeling for life science financings and related negotiations.
• Dynamic capability – Inputs can be added or changed as new or existing shareholders make commitments, providing real-time data throughout the financing process.
• Flexible delivery – Clients can choose to run the tool themselves or have our team create and run the tool on their behalf as a managed service.  
• Fail-safe measures – Quality control is built into the tool to ensure accuracy and ease of use.
• Longer-term view – We understand the legal and other requirements that drive how to format, round and structure the pro-forma to transition smoothly from the pre-financing model to the pro forma cap table and ultimately to the post-financing cap table.